[go: up one dir, main page]

NO20015257L - Farmasöytisk sammensetning for å hindre, behandle eller utviklingsinhibere enkel retinopati og preproliferativ retinopati - Google Patents

Farmasöytisk sammensetning for å hindre, behandle eller utviklingsinhibere enkel retinopati og preproliferativ retinopati

Info

Publication number
NO20015257L
NO20015257L NO20015257A NO20015257A NO20015257L NO 20015257 L NO20015257 L NO 20015257L NO 20015257 A NO20015257 A NO 20015257A NO 20015257 A NO20015257 A NO 20015257A NO 20015257 L NO20015257 L NO 20015257L
Authority
NO
Norway
Prior art keywords
retinopathy
pharmaceutical composition
developmentally
treat
prevent
Prior art date
Application number
NO20015257A
Other languages
English (en)
Other versions
NO327446B1 (no
NO20015257D0 (no
Inventor
Shizue Nakagawa
Yasutaka Nagisha
Hitoshi Ikeda
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20015257L publication Critical patent/NO20015257L/no
Publication of NO20015257D0 publication Critical patent/NO20015257D0/no
Publication of NO327446B1 publication Critical patent/NO327446B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015257A 1999-04-28 2001-10-26 Anvendelse av en forbindelse som har angiotensin II antagonistisk aktivitet, et prodrug derav eller et salt derav. NO327446B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12149899 1999-04-28
PCT/JP2000/002766 WO2000066161A1 (en) 1999-04-28 2000-04-27 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy

Publications (3)

Publication Number Publication Date
NO20015257L true NO20015257L (no) 2001-10-26
NO20015257D0 NO20015257D0 (no) 2001-10-26
NO327446B1 NO327446B1 (no) 2009-06-29

Family

ID=14812676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015257A NO327446B1 (no) 1999-04-28 2001-10-26 Anvendelse av en forbindelse som har angiotensin II antagonistisk aktivitet, et prodrug derav eller et salt derav.

Country Status (23)

Country Link
US (2) US7064141B1 (no)
EP (1) EP1197223B1 (no)
KR (1) KR100865059B1 (no)
CN (1) CN1172719C (no)
AT (1) ATE289204T1 (no)
AU (1) AU774799B2 (no)
BR (1) BR0010084A (no)
CA (1) CA2371554C (no)
CZ (1) CZ301913B6 (no)
DE (1) DE60018186T2 (no)
DK (1) DK1197223T3 (no)
ES (1) ES2233362T3 (no)
HU (1) HU226948B1 (no)
MX (1) MXPA01010923A (no)
NO (1) NO327446B1 (no)
NZ (1) NZ514855A (no)
PL (1) PL196895B1 (no)
PT (1) PT1197223E (no)
RU (1) RU2239454C2 (no)
SI (1) SI1197223T1 (no)
SK (1) SK286859B6 (no)
WO (1) WO2000066161A1 (no)
ZA (1) ZA200108527B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
JP4484427B2 (ja) * 2001-12-03 2010-06-16 武田薬品工業株式会社 インスリン抵抗性改善剤
TW200304812A (en) * 2002-03-08 2003-10-16 Sankyo Co An eye drop containing a tetrazole derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US8912225B2 (en) 2004-08-31 2014-12-16 Pitney Pharmaceuticals Pty Limited VEGF inhibition
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
CN101163474B (zh) * 2005-04-21 2012-02-22 参天制药株式会社 角膜结膜病变治疗剂
WO2007066678A1 (ja) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
PE20130210A1 (es) * 2007-03-28 2013-03-11 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
DE4201554A1 (de) * 1992-01-22 1993-07-29 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH0789957A (ja) * 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
WO1995021609A1 (en) 1994-02-08 1995-08-17 Ciba-Geigy Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
JPH09210183A (ja) * 1996-01-31 1997-08-12 Suzuki Motor Corp 動力伝達装置
WO1997036874A1 (en) * 1996-03-29 1997-10-09 Smithkline Beecham Corporation Eprosartan dihydrate and a process for its production and formulation
CA2577233C (en) * 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ES2182334T3 (es) * 1997-06-27 2003-03-01 Smithkline Beecham Corp Monohidrato de eprosartan.
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
PL198875B1 (pl) * 1997-08-06 2008-07-31 Smithkline Beecham Corp Kompleks kwasu (E)-α-[2-n-butylo-1-[(4-karboksyfenylo)metylo]-1H-imidazol-5-ilo]metyleno-2-tiofenopropionowego arginylu, sposób jego wytwarzania, kompozycja farmaceutyczna zawierajaca ten związek oraz jego zastosowanie
ZA991706B (en) 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
DK1096932T3 (da) * 1998-07-10 2007-10-15 Novartis Pharma Ag Antihypertensiv kombination af valsartan og calciumkanalblokker
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
JP2000159671A (ja) * 1998-12-01 2000-06-13 Takeda Chem Ind Ltd 血管新生阻害剤

Also Published As

Publication number Publication date
EP1197223A4 (en) 2003-10-29
KR20020015315A (ko) 2002-02-27
DK1197223T3 (da) 2005-05-30
AU4143400A (en) 2000-11-17
AU774799B2 (en) 2004-07-08
CN1348385A (zh) 2002-05-08
KR100865059B1 (ko) 2008-10-23
US7064141B1 (en) 2006-06-20
SK15452001A3 (sk) 2002-04-04
SK286859B6 (sk) 2009-06-05
RU2239454C2 (ru) 2004-11-10
ZA200108527B (en) 2002-10-17
PL196895B1 (pl) 2008-02-29
DE60018186T2 (de) 2005-12-29
HUP0200890A2 (hu) 2002-11-28
ATE289204T1 (de) 2005-03-15
NO327446B1 (no) 2009-06-29
PT1197223E (pt) 2005-04-29
ES2233362T3 (es) 2005-06-16
CZ301913B6 (cs) 2010-07-28
PL350554A1 (en) 2002-12-16
SI1197223T1 (no) 2005-08-31
HUP0200890A3 (en) 2002-12-28
CA2371554C (en) 2009-06-09
BR0010084A (pt) 2002-01-15
EP1197223A1 (en) 2002-04-17
DE60018186D1 (de) 2005-03-24
EP1197223B1 (en) 2005-02-16
US20060189669A1 (en) 2006-08-24
HU226948B1 (en) 2010-03-29
MXPA01010923A (es) 2002-06-21
CA2371554A1 (en) 2000-11-09
NO20015257D0 (no) 2001-10-26
WO2000066161A1 (en) 2000-11-09
CN1172719C (zh) 2004-10-27
CZ20013804A3 (cs) 2002-04-17
NZ514855A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
GB9801690D0 (en) Therapeutic agents
TR199902033T2 (xx) Diyabet i�in s�lfonilura-glitazon sinerjik kombinasyonlar�.
BR0317696A (pt) Composição para branqueamento
ATE141131T1 (de) Fungizide wirkstoffkombinationen
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE60131138D1 (de) Antibakterielle mittel
NO20015257D0 (no) Farmasöytisk sammensetning for å hindre, behandle eller utviklingsinhibere enkel retinopati og preproliferativ retinopati
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
DK0624583T3 (da) Substituerede pyridylmethylpyridoner som angiotensin II-antagonister
SE0104248D0 (sv) Method of treatment
BR0316085A (pt) Substâcias microbicidas
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
DE60008935D1 (de) Pyridinsulfonylharnstoffderivate mit herbizider wirkung
ZA200308147B (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals.
FI961310L (fi) Synergistisiä mikrobin vastaisia koostumuksia, jotka sisältävät 2-(tiosyaanimetyylitio)bentsotiatsolia ja orgaanista happoa
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
DK1015437T3 (da) Benzoxazin- og benzothiazin-derivater og deres anvendelse i lægemidler
BR0108002A (pt) Derivados de amidas heterocìclicas

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees